miR-34a expression in human breast cancer is associated with drug resistance

Zhi-Hua Li1,*, Xueling Weng2,*, Qiu-Yun Xiong1, Jian-Hong Tu3, An Xiao4, Wei Qiu3, Yu Gong1, Er-Wei Hu1, Songyin Huang2 and Ya-Li Cao1

1Department of Breast Surgery, The Third Hospital of Nanchang City, Key Laboratory of Breast Diseases, Nanchang, Jiangxi 330009, P.R. China
2Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, P.R. China
3Department of Pathology, The Third Hospital of Nanchang City, Jiangxi Breast Specialist Hospital, Nanchang, Jiangxi 330009, P.R. China
4Department of Breast Surgery, Pingxiang People’s Hospital, Pingxiang, Jiangxi 330009, P.R. China

*These authors contributed equally to this work

Correspondence to: Zhi-Hua Li, email: huazhili0802@163.com
Ya-Li Cao, email: caoyali@medmail.com.cn
Songyin Huang, email: hsongyin@126.com

Keywords: miR-34a; breast cancer; drug resistance; prognosis

Received: June 03, 2017   Accepted: October 15, 2017   Published: November 06, 2017

Copyright: Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

miR-34a is significantly down-regulated in breast cancer tissues and cell lines, which may be correlated with breast cancer multi-drug resistance (MDR). Here, we conducted cell-based experiments and clinical studies in a cohort of 113 breast cancer samples to analyze miR-34a expression and breast cancer MDR. Expression of miR-34a is down-regulated in the multi-drug resistant MDR-MCF-7 cells compared with its parental cells. Patients with miR-34a low expression had poorer overall survival (OS) and disease free survival (DFS) in comparison with those with high expression. Transfecting miR-34a mimics into MDR-MCF-7 breast cancer cells led to partial MDR reversal. Compared with the control group, miR-34a significantly reduced both the mRNA and protein expressions of BCL-2, CCND1 and NOTCH1, but no obvious changes were found in P53 or TOP-2a expression. In breast cancer tissue samples, the expression of miR-34a was related to BCL-2, CCND1 and NOTCH1, but not to HER-2, P53 and TOP-2a. Altogether, our findings suggest that miR-34a is an MDR and prognosis indicator of breast cancer, which may participate in the regulation of drug-resistant breast cancer by targeting BCL-2, CCND1, and NOTCH1.

INTRODUCTION

Breast cancer is the most common cancer in females worldwide. Although in recent years, the early detection and systemic treatment of breast cancer has made exciting progress, it remains a major cause of cancer related death because of metastasis, relapse, and treatment failure. Multi-drug resistance (MDR) is common in tumor cells and is often the origin of treatment failure. Increasing evidence indicated that the MDR of breast cancer is caused by varying mechanisms. A previous study [1] summarized that the mechanisms breast cancer MDR include the abnormal expression of multidrug-resistance 1 (MDR1), breast cancer resistance protein (BCRP) and other anticancer genes that affect the effectiveness of drugs by decreasing their breast cancer intracellular concentration. MDR mechanisms also include the expression of anti-apoptotic genes such as BCL-2, and P53, which cause cancer cells to resist chemotherapy-mediated apoptosis. In addition, DNA methylation and histone modification have also been proved to be responsible for breast cancer MDR [2–4].

MicroRNAs (miRNAs) are small non-coding RNAs (18–25 nucleotides) which regulate various biological
processes by silencing their target genes at the post-transcriptional level. Recent studies have documented that selected miRNAs, such as miR-451, miR-487a, miR-489, and miR-125b play key roles in the chemoresistance of breast cancer [5]. The gene encoding miR-34a is one of the first and well studied miRNAs associated with tumorigenesis, which is located on lp36.23. Li et al found that miR-34a is down-regulated in breast cancer cell lines and tissues, compared with normal cell lines and the adjacent non-tumor tissues, respectively [6]. Previous studies have reported that ectopic expression of miR-34a inhibits the growth, invasion and migration of breast cancer cells [7]. It also contributes to drug resistance of breast cancer by targeting a variety of oncogenes. For example, by directly interacting with BCL-2 and CCND1, miR-34a is reported to be associated with docetaxel resistance [8], while by targeting NOTCH1 and PRKD1, miR-34a modulates chemosensitivity of breast cancer cells to adriamycin [9], and stimulates breast cancer stemness and drug resistance, respectively [10].

MDR is a very complex and multifactorial interaction process. However, the role of miR-34a in the MDR process of breast cancer is still unclear. This study aims to reveal miR-34a expression in breast cancer and its potential role in drug resistance using in vitro experiments and clinical studies.

RESULTS

Differences of miR-34a expression in drug resistant MCF-7 (MDR-MCF-7) cells and parental MCF-7 cell lines

The MDR-MCF-7 cells and parental MCF-7 cells grew well in the logarithmic phase, but the former has more heteromorphism than the latter (Figure 1A). The expression of miR-34a was detected in the two cell lines using qRT-PCR. Expression of miR-34a in MDR-MCF-7 cells was 46% lower than that in MCF-7 cells ($P < 0.05$, Figure 1B).

As shown in Figure 1C and 1D, the western-blot result indicated the expression of MDR1 in MDR-MCF-7 cells was nearly twice as high as that in MCF-7 cells.

Drug sensitivity analysis of MDR-MCF-7 cells transfected with a miR-34a mimic

After transfection of NC-RNA or miR-34a mimics into MDR-MCF-7 cells, MTT assay was employed to detect cell responses to different drug treatments, which include doxorubicin (DOX), cyclophosphamide, docetaxel, and 5-fluorouracil (5-FU). The inhibition concentration curves were plotted to calculate the IC$_{50}$ values. The IC$_{50}$ values in the miR-34a mimic treatment group were lower than those in the NC-RNA mimic group (Table 1), which means that the drug resistance of

Figure 1: The different expressions of miR-34a in MCF-7 and MDR-MCF-7 cells. (A) The morphology of MCF-7 and MDR-MCF-7 cells. (B) Compared with MCF-7 parental cells, the expression of miR-34a in MDR-MCF-7 multi-drug resistant breast cancer cells was 46% down-regulated. (C–D) The expression of MDR1 in MDR-MCF-7 cells was significantly higher than in MCF-7 cells. *$P < 0.05$, as compared with the NC control.
MDR-MCF-7 cells was partially reversed after transfection with a miR-34a mimic.

**Apoptosis and cell cycle distribution of MDR-MCF-7 breast cancer cells transfected with a miR-34a mimic**

The apoptosis rate of MDR-MCF-7 cells in the miR-34a mimic group was significantly higher than that of the NC-RNA mimic group \( (t = 11.094, P = 0.008) \) according to flow cytometry detection. As for analysis of cell cycle distribution, compared with the NC-RNA mimic treatment, a higher portion of cells transfected with stayed in mitosis (\( G_2/M \) phase) with miR-34a mimic transfection in was higher \( (t = 19.919, P = 0.003) \), and the proportion of cells in \( G_0/G_1 \) phase was lower \( (t = 20.352, P = 0.002) \). However, no significant difference in the proportion of cells in \( S \) phase was detected between the two groups \( (t = 3.395, P = 0.077) \). The data was shown in Figure 2A–2D and Table 2.

**MiR-34a decrease the expression of MDR1 protein in MDR-MCF-7**

As shown in Figure 2E and Supplementary Figure 1, after miR-34a mimics were transfected into, the expression of MDR1 protein in MDR-MCF-7 cells with miR-34a mimic transfection decreased compared with NC-RNA treatment \( (P < 0.05) \). But knockdown MDR1 in MDR-MCF-7 cells, significant changes of miR-34a expression were not found (Figure 2F).

**Recovering miR-34a in MDR-MCF-7 breast cancer cells, the expression changes of TOP-2a, P53, BCL-2, CCND1, NOTCH1**

After miR-34a or NC-RNA mimics were transfected into MDR-MCF-7 cells, expressions of P53, BCL-2, TOP-2a, CCND1, and NOTCH1 were detected using qRT-PCR or Western-blot. The mRNA expression of P53 and TOP-2a had no significant change compared with NC-RNA mimic group, but the expression of BCL-2, CCND1 and NOTCH1 in the miR-34a mimic group was reduced to 0.43 ± 0.02 (\( n = 3, P = 0.03 \)), 0.37 ± 0.01 (\( n = 3, P = 0.01 \)) and 0.47 ± 0.01 (\( n = 3, P = 0.02 \)), respectively (Figure 3A).

**miR-34a levels were correlated inversely with drug resistance and poor prognosis of breast cancer patients**

To address whether miR-34a has clinical relevance in breast cancer drug resistance, the expression levels of miR-34a in 113 FFPE tissue samples were examined by qRT-PCR and the expressions of these genes above were analyzed by immunohistochemistry (IHC). The significance was found between miR-34a levels and the expressions of BCL-2, CCND1 and NOTCH1 \( (P < 0.001, P = 0.0232, P = 0.0086) \). But the correlations were not found between the expression levels of miR-34a and the expressions of HER-2, TOP-2a and P53 \( (P = 0.2190, P = 0.3476, P = 0.7386) \). The analysis data was shown in Figure 4. The correlation between miR-34a expression and clinicopathological indicators was shown in Supplementary Table 1.

To evaluate the prognostic value of miR-34a expression in breast cancer, the Kaplan-Meier survival curve was used to analyze the patient survival outcome. The expression levels of miR-34a in breast cancer were categorized as low or high at the cut-off value of the median. Survival analysis showed that patients with low miR-34a expression had poorer overall survival (OS) and disease free survival (DFS) compared with those with high expression \( (P = 0.003 \) and 0.007, respectively) (Figure 5A and 5B), revealing that low miR-34a expression indicates poor prognosis for breast cancer patients.

**DISCUSSION**

miRNAs are a class of highly conserved, endogenous, small non-coding RNA that are involved in regulation at the post-transcriptional level. The miR-34a gene is located at lp36.23. MiR-34a was firstly identified

---

**Table 1: Drug sensitivity of MDR-MCF-7 transfected with NC-RNA and miR-34a mimic**

| DRUG | MDR-MCF-7 IC50 (umol/L (x ± s)) | NC–RNA mimic | miR-34a mimic | RI | t | P |
|------|-------------------------------|--------------|----------------|----|----|---|
| ADM  | 316.8 ± 43.6                  | 23.2 ± 13.1  | 13.7           | 16.67 | 0.004 |
| DOC  | 37.5 ± 13.3                   | 6.9 ± 2.4    | 5.4            | 4.86  | 0.04  |
| CTX  | 9.7 ± 3.7                     | 3.1 ± 1.9    | 3.1            | 6.35  | 0.024 |
| 5-FU | 6.3 ± 1.4                     | 2.9 ± 1.1    | 2.2            | 19.63 | 0.003 |

*NC-RNA: Negative control RNA.*
as a target of P53 and silenced in various human cancers acted as an important tumor suppressor [11, 12]. Increasing evidence has indicated that miR-34a antagonized many different oncopgenic processes, such as inhibiting tumor cell differentiation, proliferation, migration, and invasion, and thus increasing apoptosis and cell arrest [13, 14]. Besides, miR-34a downregulation in different types of cancers has been reported to be correlated with cancer multidrug resistance [15]. Recent research has shown that increasing the intracellular expression of miR-34a can significantly increase the sensitivity of cancer cells to cisplatin [16]. Reducing the expression of miR-34a caused resistance in DLD-1 colorectal cancer cells to 5-FU [17], and oxaliplatin induced downregulation of miR-34a and increased drug resistance by activating macroautophagy in CRC cells [18]. Kojima et al reported that downregulation or lost expression of miR-34a in PC3PR pancreatic cancer cells led to resistance to taxanes through increasing expression of STIRT1 and BCL-2 [19]. Our study finds that the expression of miR-34a in MDR-MCF-7 cells is lower than that in sensitive parental MCF-7 cells, indicating that miR-34a may be involved in the process of multi-drug resistance in breast cancer.

MDR usually links with treatment failure and poor prognosis of breast cancer patients. It is reported that miR-34a is a diagnostic marker to predict clinical pathological

![Figure 2: miR-34a effect on the drug-resistance changes of MDR-MCF-7 cells.](image)

(A) miR-34a mimics increase the proportion of cells in mitosis (G2/M phase) and decreased the proportion of MDR-MCF-7 cells in G0/G1 phase compared with NC-RNA mimics. (B) miR-34a mimics enhance the apoptotic rate of MDR-MCF-7 cells compared with NC-RNA mimics. (C–D) The representative flow cytometry figures were also shown. (E) miR-34a decrease the expression of MDR1 protein in MDR-MCF-7 compared with NC-RNA. (F) The expression of miR-34a was not change in MDR-MCF-7 cells after knocking down MDR1. Bars indicate the mean ± SD from at least three independent experiments. *P < 0.05, as compared with the NC control.
features and outcomes of breast cancer [18, 20]. Our study found that patients with miR-34a low expression had poorer OS and DFS compared to those with high expression, which is consistent with other studies [21, 22], suggesting that low miR-34a expression indicates poor prognosis for breast cancer patients.

Wen et al found micellar delivery of miR-34a modulator rubone could reverse chemoresistance and further enhance the therapeutic efficacy of paclitaxel (PTX) in PTX-resistant prostate cancer [23]. Deng et al suggested that co-delivery of DOX and miR-34a could achieve synergistic effects on tumor suppression of triple negative breast cancer [24]. Our study discovered that in MDR-MCF-7 cells transfected with miR-34a mimics, the IC50 values of DOX, cyclophosphamide, docetaxel and 5-FU decreased to varying degrees, while the apoptosis rate increased and cells were arrested in G0/G1 phase. After miR-34a mimics were transfected into MDR-MCF-7 breast cancer cells, the expression of MDR1 protein decreased, which implies that miR-34a mimic can partially reverse the drug resistance of MDR-MCF-7 cells, although the underlying molecular mechanism remains unclear. Our result also confirmed that miR-34a may be a therapeutic agent against MDR of breast

| Groups            | G0/G1 (%) | S (%) | G2/M (%) | Apoptosis (%) |
|-------------------|-----------|-------|----------|---------------|
| NC–RNA mimic      | 51.6 ± 3.1 | 27.2 ± 7.1 | 21.2 ± 3.5 | 13.1 ± 1.1    |
| miR-34a mimic     | 65.7 ± 4.3 | 22.3 ± 4.6 | 12 ± 2.7  | 36.8 ± 2.6    |

*NC-RNA: Negative control RNA. **P < 0.05.

Table 2: The cell cycle distribute and apoptosis of MDR-MCF-7 transfected with NC-RNA and miR-34a mimic

Figure 3: Recovering miR-34a in MDR-MCF-7 cells, the expression of TOP2A, P53, BCL-2, CCND1, NOTCH1. (A–C) After miR-34a transfection into MDR-MCF-7 breast cancer cells, the expression of BCL-2, CCND1 and NOTCH1 mRNA and protein were both reduced, while the expression of P53 and TOP-2a did not significantly change. *P < 0.05, as compared with the NC control.

www.impactjournals.com/oncotarget

106274 Oncotarget
cancer, which has been a breakthrough in the treatment of HCC patients [25].

The mechanism of multidrug resistance in breast cancer is very complex. Various studies have demonstrated a series of targeted genes and multiple signaling pathways involved in the regulation of multidrug resistance. Inactivation of P53 as well as activation of PI3K/Akt, RAS/RAF and NF-κB pathways can confer drug resistance to the cells. BCL-2 protein family members leads to the stability of the outer mitochondrial membrane and mitigation of apoptosis, which is another main mechanism facilitating MDR [16]. CCND1, a protein related to cell cycle, was demonstrated to be involved in above EGFR-mediated G1/S transition, which contributed to the multidrug resistance in breast cancer cells [26]. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer [27]. The NOTCH signaling pathway is a highly conserved signaling pathway. By targeting NOTCH1, miR-34a can regulate the chemosensitivity of breast cancer to DOX [9]. Breast cancer stem cells are considered the source of drug resistance and relapse, thus representing another important mechanism of drug resistance in breast cancer. Studies have shown that NOTCH1 activation is beneficial to maintaining the phenotype of cancer stem cells and promote brain metastasis of breast cancer cells [28]. Additionally, miR-34a can inhibit the proliferation of breast cancer stem cells by down-regulating the NOTCH1 pathway, and miR-34a increases the sensitivity of breast cancer cells to PTX [29]. The TOP-2a gene is located on the 17q21-q22 region and is the target of anthracycline drugs. Changes in intracellular TOP-2a expression and activity form another important mechanism of breast cancer resistance to chemotherapy [30]. The HER-2 gene is located adjacent to the TOP-2a gene and promotes cell proliferation by participating in transmembrane signal transduction in a variety of ways. It increases susceptibility

Figure 4: The relationship between miR-34a expression and the expression of HER-2, TOP2A, P53, BCL-2, CCND1, NOTCH1 in breast cancer tissue samples. (A–F) In breast cancer tissue samples, the expression of miR-34a was related to BCL-2, CCND1 and NOTCH1 (P < 0.001, P = 0.0232, P = 0.0086), but not to HER-2, P53 and TOP-2a (P = 0.2190, P = 0.3476, P = 0.7386).
Figure 5: Low level of miR-34a expression was correlated with poor prognosis. (A) OS curves for 113 patients with low or high miR-34a expression. Kaplan-Meier and log-rank analyses were used. Low levels of the miR-34a were markedly correlated with shorter overall survival. (B) DFS curves for 113 patients with low or high miR-34a expression. Low level of the miR-34a was markedly correlated with shorter disease-free survival. All data are shown as the mean ± SE, *P < 0.05.

Figure 6: The expression of HER-2, TOP2A, P53, BCL-2, CCND1, NOTCH1 protein were by immunohistostaining. (A–B) Positive cells in breast cancer tissues (SP × 200).
to anthracycline drugs by directly or indirectly enhancing the activity of TOP-2α [31–32]. Meta-analyses suggest that HER-2 and/or TOP-2α are predictive indicators of chemotherapy resistance in breast cancer [33]. In order to identify miR-34a targets in drug resistance modulation of breast cancer, we investigated the relationship between miR-34a expression and these above-mentioned targeted genes. Our results suggested transfection of miR-34a mimics into MDR-MCF-7 breast cancer cells reduced mRNA and protein expression of BCL-2, CCND1, and NOTCH1 without significantly changing expression of P53 and TOP-2α in vitro. In breast cancer tissue samples, the expression of miR-34a was related to BCL-2, CCND1, and NOTCH1, but not to HER-2, P53, and TOP-2α. This indicated that miR-34a is involved in the regulation of drug-resistant breast cancer and may target BCL-2, CCND1, and NOTCH1. These findings are consistent with a bioinformatic analysis (http://www.targetscan.org/) and previous literature reports [8, 29, 34], which were shown in Figure 6. Of course, there are some disagreements on the regulatory effect of P53 on miR-34a. Park et al suggested that the reduced level of miR34 is related to the dysregulation of P53 in chemoresistant MDR-MCF-7 cells [35]. However, the expression of P53 did not change significantly when miR-34a was up-regulated. We also found that P53 protein was expressed in a higher level in MDR-MCF7 cells compared with parental MCF-7 cells, which was shown in Supplementary Figure 2. We think there are two reasons for the inconsistent results. Firstly, the positive expression of P53 IHC incompletely represents mutations status of P53 [36]. Secondly, miR-34a might be regulated by other factors which work independent of P53. miR-34a expression can be affected in a significant proportion of breast tumors independent of P53 [37].

In short, miR-34a can serve as an indicator of MDR and prognosis of breast cancer. MiR-34a may participate in the regulation of drug-resistant breast cancer by targeting BCL-2, CCND1, and NOTCH1.

MATERIALS AND METHODS

Patients

Patients included in this study were retrospectively selected from the database of breast cancer patients treated between February 2008 and June 2010 at the Third Hospital of Nanchang. All patients are female, which were diagnosed with invasive breast cancer staging II–III, and had perfect follow-up data after treatment. After comprehensively skimming the case archives of every single patient, 113 patients were enrolled in our study. Study protocol was approved by the Ethics Committee of the Third Hospital of Nanchang (No. 20071208), and all study patients signed consent forms. All patients were treated according to the guidelines for the clinical diagnosis and treatment of breast cancer. Adjuvant chemotherapy used FAC (5-fluorouracil + doxorubicin + cyclophosphamide) or AC-T (doxorubicin and cyclophosphamide sequential paclitaxel). ER-positive tumors were treated with endocrine therapy. If axillary lymph node metastasis were ≥4, tumor size was ≥5 cm or axillary lymph node metastasis was from 1 to 3 with two or more risk factors for recurrence, patients were treated with chest wall + supraclavicular radiotherapy. The median age of patients at diagnosis was 46.3 years (range 31–73 years). The tumor characteristics are shown in Table 3.

Cell culture and determination of drug sensitivity

The MCF-7 human breast cancer cell line and the MDR-MCF-7 multi-drug resistant cell line were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI 1640 medium (Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% FBS, 105 U/L penicillin and 100 mg/L streptomycin (Gibco Laboratories, Grand Island, NY, USA). All cells were cultured at 37°C in the presence of 5% CO2. MDR-MCF-7 cells were exposed to 0.05 μM doxorubicin for the maintenance of the MDR phenotype, but cultured in drug-free medium for at least one week prior to experimental study. The cell survival rate was detected using MTT (Sigma-Aldrich, Dorset, UK) assay, then concentration inhibition curves were plotted to calculate the IC50 of doxorubicin, docetaxel, and 5-fluorouracil in MCF-7 and MDR-MCF-7 cells (RI = IC50 (resistant cells)/IC50 (sensitive cells)). Experiments were repeated three times.

RNA extraction

Total RNA was extracted from frozen cells using TRIzol® reagent according to the manufacturer’s protocol (Invitrogen, Paisley, UK) and stored at −80°C until use. Archival formalin-fixed paraffin-embedded (FFPE) tissue samples were obtained from the Pathology Department of the Third Hospital of Nanchang. Small punches of FFPE blocks were deparaffinized and treated with proteinase K. RNA was isolated from human FFPE tissue samples using the miRNeasy FFPE Kit (Qiagen, Hilden, Germany), and RNA quantity and quality were determined using agarose gel electrophoresis and a UV spectrophotometer following manufacturer’s guidelines.

Reverse transcription and quantitative real-time PCR

For miR-34a analysis, quantitative real-time-PCR (qRT-PCR) was performed using a TaqMan Reverse Transcription Kit and a TaqMan MicroRNA Assay Kit (Applied Biosystems, Foster City, CA, USA) with U6 as the control. For mRNA analysis, qRT-PCR was carried out with SYBR Green Master Mix (Roche Diagnostics).
GmbH, Mannheim, Germany); β-actin was used as a control. Primer sequences for mature miR-34a, U6 snRNA and miRNA target genes were synthesized by Shanghai Invitrogen Company and are shown in Table 4. All experiments were carried out in triplicate. The data were analyzed according to the comparative Ct method ($2^{-\Delta\Delta C_T}$).

**Transfection of miR-34a and NC-RNA mimics into the MDR-MCF-7 breast cancer cell line**

MDR-MCF-7 cells in the logarithmic phase were collected using trypsin digestion and centrifugation. Then, cells were seeded in 24-well plates and cultured in suspension in complete medium without antibiotics. When cells achieved 30–50% adherence, miR-34a and NC-RNA mimics (the structural and synthesis information was shown in Figure 6) were transfected into the cells using Lipofectamine 2000 according to the manufacturer’s instructions. After incubating for 6 hours at 37°C under 5% CO$_2$ concentration, the transfection efficiency (up to 90%) was observed with a fluorescence inverted phase contrast microscope. The medium was replaced for new cultures, which were then incubated for 24 hours.

Changes in cell sensitivity to doxorubicin, docetaxel and 5-fluorouracil were detected using an MTT assay and the cell-cycle distribution and apoptosis changes were detected using flow cytometry.

Table 3: Clinicopathologic characteristics of patients cohort

| Variable                  | N  | %   |
|---------------------------|----|-----|
| menopausal status         |    |     |
| Pre-menopausal            | 69 | 61.1%|
| Post-menopausal           | 44 | 38.9%|
| Staging                   |    |     |
| I+ IIa                    | 58 | 51.3%|
| IIb + III                 | 55 | 48.7%|
| Histologic type           |    |     |
| Invasive ductal carcinoma | 78 | 69%  |
| Invasive lobular cancer   | 18 | 15.9%|
| Mixed type                | 7  | 6.2% |
| Other types               | 10 | 8.8% |
| ER status                 |    |     |
| ER negative               | 40 | 35.4%|
| ER positive               | 73 | 64.6%|
| PR status                 |    |     |
| PR negative               | 47 | 41.6%|
| PR positive               | 66 | 58.4%|
| HER-2 status              |    |     |
| HER-2 negative            | 71 | 65.5%|
| HER-2 positive            | 42 | 34.5 |
| Surgical types            |    |     |
| Breast conservation       | 13 | 11.5%|
| Mastectomy                | 100| 88.5%|
| chemotherapy              |    |     |
| FEC regimen               | 51 | 45.1%|
| CET or AC-T regimen       | 62 | 54.9%|
| Adjuvant radiotherapy     |    |     |
| YES                       | 53 | 46.9%|
| No                        | 60 | 53.1%|
After transfection with miR-34a and NC-RNA mimics for 48 h, MDR-MCF-7 breast cancer cells were gently scraped, washed twice with chilled PBS (4°C), and suspended at a concentration of $1 \times 10^6$ cells/mL for flow cytometry detection. For cell cycle analysis, target cells were fixed in 75% ethanol and stained with propidium iodide (Sigma Aldrich) supplemented with RNase A (Roche). The Annexin V-APC/7-AAD apoptosis kit (KeyGEN Biotech, Nanjing, China) was used for apoptosis assays. Each set of two wells was analyzed 3 times with a BD Canto II flow cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed using CellQuest software.

**Western blot**

After transfection with miR-34a and NC-RNA mimics for 48 h, MDR-MCF-7 cells were washed 3 times with chilled PBS, and as much residual washing liquid as possible was absorbed. Cells were lysed in RIPA buffer (Sigma). The samples were separated using SDS-PAGE and transferred to PVDF membranes. GAPDH was used as an endogenous control. The proteins of miRNA target genes (P53, BCL-2, TOP-2a, CCND1, NOTCH1) were detected using the Western blot method with ECL development and by analyzing the strength of the strip.

**Immunohistochemistry**

For IHC, paraffin sections were treated with the following antibodies: TOP2A (Dilution 1:1000; Dako, UK), P53 (Dilution 1:250; Cloning DO7; Dako, UK), BCL-2 (Dilution 1:250; clone 124; Dako, Ely, UK), CCND1 (Dilution 1:1000; SC-8396; Zhongshan Biologicals, Beijing), NOTCH1 (Dilution 1:100; Santa Cruz Biotechnology). Fixed and paraffin-embedded tissue sections were incubated by two independent observers and scored with a scale ranging from 0 to 3 points: 0 score, lack of positive tumor cells; 1 score, cells were stained weakly or <10% positive tumor cells; 2 score, moderate staining or 10–50% positive tumor cells; 3 score, severe staining or >50% positive tumor cells. 0–1 score was defined as Negative expression and 2–3 score as Positive expression (Positive image shown in Figure 7).

### Table 4: Primer sequences for miR-34a, U6 and miRNA target genes

| Gene     | Forward primer(5′→3′)          | Reverse primer(5′→3′)          |
|----------|--------------------------------|--------------------------------|
| miR-34a  | GGGTGGGAGTTGTCTTAGC            | CAGTGCGTGTGGTGGAGGT            |
| U6       | GTGCTCGCTCGGCAGCA              | CAAAATATGGAAAGCCTTC           |
| P53      | TCTTCTACGACGTCCCTG            | GCTTGCTACCTCGCTTAGT           |
| Bcl-2    | ACACCCCCCATTCTCTCTGCC          | AATCTCCCCCCAGTCTACCC          |
| Top-2a   | GCAGTGGTGCTGGTCTCAA           | ACAATTGCGCTAAGCTC            |
| CCND1    | GTCTTCCCCGGCGCATGACTAC         | GGAAGCGTGTGAGCGCTAGTAGG       |
| Notch1   | CACTGTGGGCGGGTCC              | GTGTATGCTGGCTGGACCAT          |
| β-actin  | TCATGAAGTGTGACGGACATC          | CAGGAGGAGGAATGATCTTGATCT     |

Figure 7: A sketch of miR-34a and their target genes.
Statistical analysis

Statistical tests were carried out using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism 5. The differences between groups were analyzed using a Student’s t-test when only 2 groups or 1-way analysis of variance when more than 2 groups were compared. Differences in frequency were assessed by Chi-square test. The cut-off for the follow-up period was June 30, 2015. DFS and OS curves were calculated using the Kaplan-Meier method and compared by log-rank testing. A \( P < 0.05 \) was considered statistically significant.

Ethics approval

This study was conducted with the approval of the Ethics Committee at the Third Hospital of Nanchang City (NO. 20071208). Written informed consent was obtained from all patients. Research carried out is in compliance with the Helsinki Declaration.

Abbreviations

MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MDR, Multi-drug resistance; BCRP, breast cancer resistance protein; FAC, 5-fluorouracil, doxorubicin and cyclophosphamide; CET, cyclophosphamide, epirubicin and taxane; AC-T, cyclophosphamide and epirubicin-taxanes; ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; FFPE, formalin-fixed paraffin-embedded; IHC, immunohistochemistry; BC, breast cancer; HCC, hepatocellular carcinoma; DFS, Disease-free survival; OS, Overall survival; TP53, tumor protein p53.

Author contributions

Zhi-hua Li, Songyin Huang and Ya-li Cao contributed to the design of the study, drafted the manuscript, and analyzed and interpreted the data. Xueling Weng, Qiu-yun Xiong, An Xiao, Yu Gong and Er-wei Hu assisted with quantitative data collection and patient follow-up. Jianhong Tu and Wei Qu reviewed the tumor sections of the patients. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

We thank Liang Xu for his assistance with cell cultures and helpful suggestions throughout the experiments.

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

FUNDING

This work was supported by grants from the Science and Technology Foundation of the Guangdong Province (2014A050503029), the National Natural Science Foundation of China (81102020), the Science and Technology Support Program of Jiangxi Province (20122BBG70111), the Science and Technology Foundation of the Guangdong Province (2014A050503029), and the Sun Yat-sen Initiative Program for Scientific Research (YXQH201701).

REFERENCES

1. Videira M, Reis RL, Brito MA. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochim Biophys Acta. 2014; 1846:312–25.
2. Kovalev AA, Tsvetaeva DA, Grudinskaja TV. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 2013; 35:287–90.
3. Wang Y, Wang X, Zhao H, Liang B, Du Q. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and BCL-2 overexpression. J Chemother. 2012; 24:348–57.
4. Sandhu R, Roll JD, Rivenbark AG, Coleman WB. Dysregulation of the epigenome in human breast cancer: contributions of gene-specific DNA hypermethylation to breast cancer pathobiology and targeting the breast cancer methylome for improved therapy. Am J Pathol. 2015; 185:282–92.
5. Wang J, Yang M, Li Y, Han B. The Role of MicroRNAs in the Chemoresistance of Breast Cancer. Drug Dev Res. 2015; 76:368–74.
6. Li L, Xie X, Luo J, Liu M, Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Wei W, et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther. 2012; 20:2326–34.
7. Avtanski DB, Nagalingam A, Tomaszewski JE, Risbood P, Difillippantonio MJ, Saxena NK, Malhotra SV, Sharma D. Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of P53-34a axis. Mol Oncol. 2016; 10:1118–32.
8. Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 2012; 131:445–54.
9. Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ, Zhao JH, Tang JH. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting NOTCH1. Arch Med Res. 2012; 43:514–21.
10. Kim Y, Park EY, Chang E, Kang HG, Koo Y, Lee EJ, Ko JY, Kong HK, Chun KH, Park JH. A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in
breast cancer. Oncotarget. 2016; 7:14791–802. https://doi.org/10.18632/oncotarget.7443.

11. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, et al. A microRNA component of the P53 tumour suppressor network. Nature. 2007; 447:1130–4.

12. Missio G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zaronre MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014; 3:e194.

13. Saito Y, Nakaoka T, Saito H. microRNA-34a as a Therapeutic Agent against Human Cancer. J Clin Med. 2015; 4:1951–9.

14. Imani S, Wei C, Cheng J, Khan MA, Fu S, Yang L, Tania M, Zhang X, Xiao X, Zhang X, Fu J. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion. Oncotarget. 2017; 8:21362–79. https://doi.org/10.18632/oncotarget.15214.

15. Ghandadi M, Sahebkar A. MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance. Curr Pharm Des. 2016; 22:933–9.

16. Wang X, Dong K, Gao P, Long M, Lin F, Weng Y, Ouyang Y, Ren J, Zhang H. microRNA-34a sensitizes lung cancer cell lines to DDTP treatment independent of P53 status. Cancer Biother Radiopharm. 2013; 28:45–50.

17. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011; 300:197–204.

18. Sun C, Wang FJ, Zhang HG, Xu XZ, Jia RC, Yao L, Qiao PF. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macropgaugia via transforming growth factor-β/Smad4 pathway. World J Gastroenterol. 2017; 23:1816–1827.

19. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate, 2010; 70:1501–12.

20. Imani S, Zhang X, Hosseinifard H, Fu S, Fu J. The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis. Oncotarget. 2017; 8:23177–87. https://doi.org/10.18632/oncotarget.15520.

21. Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, Atitomiaä K, Heikilä P, Bartek J, Blomqvist C, Büttzow R, Nevanlinna H. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One. 2011; 6:e26122.

22. Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. Br J Cancer. 2015; 112:61–8.

23. Wen D, Peng Y, Lin F, Singh RK, Mahato RI. Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer. Cancer Res. 2017; 77:3244–3254.

24. Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, Xiao X, Yang Y, Sheng W, Wu Y, Zeng Y. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014; 35:4333–44.

25. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS. Phase I study of MRX34, a liposomal miR-34a mimic,administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017; 35:180–188.

26. Chen SJ, Luan J, Zhang HS, Ruan CP, Xu XY, Li QQ, Wang NH. EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells. Mol Biol Rep. 2012; 39:5465–71.

27. Tanioka M, Sakai K, Sudo T, Sakuma T, Kajimoto K, Hirokaga K, Takao S, Negoro S, Minami H, Nakagawa K, Nishio K. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer. Breast Cancer Res Treat. 2014; 147:513–25.

28. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, Chambers AF. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res. 2011; 9:834–44.

29. Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y, Zhao L, Li J, Yang B, Li L. MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating NOTCH1 pathway. Cancer Sci. 2015; 106:700–08.

30. Susini T, Berti B, Carriero C, Tavella K, Nori J, Vanzi E, Molino C, Di Tommaso M, Santini M, Saladino V, Bianchi S. Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer. Onco Targets Ther. 2014; 7:2111–20.

31. Glynn RW, Mahon S, Curran C, Callagy G, Miller N, Kerin MJ. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer. Oncologist. 2011; 16:949–55.

32. Fountzilas G, Dafni U, Bobos M, Kotoulia V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsas T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: a pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer. 2013; 13:163.

33. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejertsen B, Prichard KJ, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O’Malley FP, Cardoso F, et al, and HER2/TOP2A Meta-analysis Study Group. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011; 12:1134–42.
34. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of BCL-2 and SIRT1. Clin Exp Med. 2013; 13:109–17.

35. Park EY, Chang E, Lee EJ, Lee HW, Kang HG, Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, Song E, Park JH. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 2014; 74:7573–82.

36. Kim JY, Park K, Jung HH, Lee E, Cho EY, Lee KH, Bae SY, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Park YH. Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. Cancer Res Treat. 2016; 48:1338–1350.

37. Javeri A, Ghaffarpour M, Taha MF, Housshmand M. Downregulation of miR-34a in breast tumors is not associated with either P53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol. 2013; 30:413.